Unknown

Dataset Information

0

Transmission assessment surveys (TAS) to define endpoints for lymphatic filariasis mass drug administration: a multicenter evaluation.


ABSTRACT:

Background

Lymphatic filariasis (LF) is targeted for global elimination through treatment of entire at-risk populations with repeated annual mass drug administration (MDA). Essential for program success is defining and confirming the appropriate endpoint for MDA when transmission is presumed to have reached a level low enough that it cannot be sustained even in the absence of drug intervention. Guidelines advanced by WHO call for a transmission assessment survey (TAS) to determine if MDA can be stopped within an LF evaluation unit (EU) after at least five effective rounds of annual treatment. To test the value and practicality of these guidelines, a multicenter operational research trial was undertaken in 11 countries covering various geographic and epidemiological settings.

Methodology

The TAS was conducted twice in each EU with TAS-1 and TAS-2 approximately 24 months apart. Lot quality assurance sampling (LQAS) formed the basis of the TAS survey design but specific EU characteristics defined the survey site (school or community), eligible population (6-7 year olds or 1(st)-2(nd) graders), survey type (systematic or cluster-sampling), target sample size, and critical cutoff (a statistically powered threshold below which transmission is expected to be no longer sustainable). The primary diagnostic tools were the immunochromatographic (ICT) test for W. bancrofti EUs and the BmR1 test (Brugia Rapid or PanLF) for Brugia spp. EUs.

Principal findings/conclusions

In 10 of 11 EUs, the number of TAS-1 positive cases was below the critical cutoff, indicating that MDA could be stopped. The same results were found in the follow-up TAS-2, therefore, confirming the previous decision outcome. Sample sizes were highly sex and age-representative and closely matched the target value after factoring in estimates of non-participation. The TAS was determined to be a practical and effective evaluation tool for stopping MDA although its validity for longer-term post-MDA surveillance requires further investigation.

SUBMITTER: Chu BK 

PROVIDER: S-EPMC3855047 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

altmetric image

Publications

Transmission assessment surveys (TAS) to define endpoints for lymphatic filariasis mass drug administration: a multicenter evaluation.

Chu Brian K BK   Deming Michael M   Biritwum Nana-Kwadwo NK   Bougma Windtaré R WR   Dorkenoo Améyo M AM   El-Setouhy Maged M   Fischer Peter U PU   Gass Katherine K   Gonzalez de Peña Manuel M   Mercado-Hernandez Leda L   Kyelem Dominique D   Lammie Patrick J PJ   Flueckiger Rebecca M RM   Mwingira Upendo J UJ   Noordin Rahmah R   Offei Owusu Irene I   Ottesen Eric A EA   Pavluck Alexandre A   Pilotte Nils N   Rao Ramakrishna U RU   Samarasekera Dilhani D   Schmaedick Mark A MA   Settinayake Sunil S   Simonsen Paul E PE   Supali Taniawati T   Taleo Fasihah F   Torres Melissa M   Weil Gary J GJ   Won Kimberly Y KY  

PLoS neglected tropical diseases 20131205 12


<h4>Background</h4>Lymphatic filariasis (LF) is targeted for global elimination through treatment of entire at-risk populations with repeated annual mass drug administration (MDA). Essential for program success is defining and confirming the appropriate endpoint for MDA when transmission is presumed to have reached a level low enough that it cannot be sustained even in the absence of drug intervention. Guidelines advanced by WHO call for a transmission assessment survey (TAS) to determine if MDA  ...[more]

Similar Datasets

| S-EPMC5391126 | biostudies-literature
| S-EPMC4376862 | biostudies-literature
| S-EPMC3260316 | biostudies-other
| S-EPMC3814337 | biostudies-literature
| S-EPMC5536438 | biostudies-other
| S-EPMC5619835 | biostudies-literature
| S-EPMC5302837 | biostudies-literature
| S-EPMC6062125 | biostudies-literature
| S-EPMC6590784 | biostudies-literature
| S-EPMC5862496 | biostudies-literature